S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:EGRX

Eagle Pharmaceuticals Stock Forecast, Price & News

$47.86
+0.18 (+0.38%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.62
$49.00
50-Day Range
$47.68
$56.90
52-Week Range
$36.48
$58.25
Volume
86,172 shs
Average Volume
108,502 shs
Market Capitalization
$618.06 million
P/E Ratio
116.73
Dividend Yield
N/A
Beta
0.69
30 days | 90 days | 365 days | Advanced Chart
Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eagle Pharmaceuticals logo

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Headlines

Eagle Pharmaceuticals Reports Third Quarter 2021 Results
November 9, 2021 |  finance.yahoo.com
Eagle Pharmaceuticals, Inc. (EGRX)
November 1, 2021 |  sg.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
106
Year Founded
N/A

Sales & Book Value

Annual Sales
$187.80 million
Cash Flow
$1.31 per share
Book Value
$14.27 per share

Profitability

Net Income
$11.99 million
Pretax Margin
3.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
10,034,000
Market Cap
$618.06 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/01/2022

MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

327th out of 1,392 stocks

Pharmaceutical Preparations Industry

142nd out of 669 stocks

Analyst Opinion: 1.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

Is Eagle Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eagle Pharmaceuticals stock.
View analyst ratings for Eagle Pharmaceuticals
or view top-rated stocks.

How has Eagle Pharmaceuticals' stock been impacted by COVID-19?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 22.5% and is now trading at $47.86.
View which stocks have been most impacted by COVID-19
.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Eagle Pharmaceuticals
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 2.97% and a net margin of 3.14%. During the same quarter in the previous year, the firm posted $0.51 earnings per share.
View Eagle Pharmaceuticals' earnings history
.

What price target have analysts set for EGRX?

2 equities research analysts have issued 1-year price objectives for Eagle Pharmaceuticals' shares. Their forecasts range from $51.00 to $51.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $51.00 in the next year. This suggests a possible upside of 6.6% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Scott L. Tarriff, President, Chief Executive Officer & Director
  • Michael Moran, Executive VP, Chief Operating & Commercial Officer
  • Brian Cahill, Chief Financial Officer
  • Judith Ng-Cashin, Chief Medical Officer & Executive Vice President
  • Daniel O'Connor, Chief Strategy Officer

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.62%), Janus Henderson Group PLC (11.83%), Dimensional Fund Advisors LP (2.17%), Smith Graham & Co. Investment Advisors LP (1.95%), Geode Capital Management LLC (1.62%) and Renaissance Technologies LLC (1.54%).
View institutional ownership trends for Eagle Pharmaceuticals
.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Goldman Sachs Group Inc., Millennium Management LLC, BlackRock Inc., Russell Investments Group Ltd., Two Sigma Advisers LP, Smith Graham & Co. Investment Advisors LP, and Citigroup Inc..
View insider buying and selling activity for Eagle Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Balyasny Asset Management LLC, South Dakota Investment Council, Assenagon Asset Management S.A., Summit Global Investments, Krensavage Asset Management LLC, Tri Locum Partners LP, and SummerHaven Investment Management LLC.
View insider buying and selling activity for Eagle Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $47.86.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $618.06 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 106 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at [email protected].


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.